Beijing Tong Ren Tang Chinese Medicine Company (3613) Q2 2025 earnings summary

Executive summary

• Revenue for the six months ended 30 June 2025 rose 14.6% year-over-year to HK$761.7 million, with profit attributable to owners up 6.9% to HK$234.9 million.

• The group expanded its Hong Kong retail presence, upgraded store image, and enhanced product packaging to boost market appeal.

• Strategic cooperation with China Duty Free International and international expansion, including product launches in New Zealand and cultural initiatives in the Middle East and Cambodia, supported global growth.

• Production upgrades and R&D achievements, including new product registrations and patents, improved cost competitiveness and product portfolio.

Financial highlights

• Gross profit increased 2.5% year-over-year to HK$463.0 million.

• Profit before income tax was HK$289.7 million, up 2.1% year-over-year.

• Earnings per share rose to HK$0.28 from HK$0.26.

• Cash and bank balances increased 10.2% to HK$2,005.5 million as of 30 June 2025.

• No interim dividend was declared for the period.

Outlook and guidance

• The group anticipates continued growth in the pharmaceutical and Chinese medicine sectors, driven by population aging and rising healthcare demand.

• Plans include deepening R&D, expanding the proprietary product matrix, and accelerating online and offline business expansion.

• Focus remains on high-quality development and strengthening core competitiveness.